United Therapeutics Corporation (UTHR) Financials

UTHR Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 6.7 billion 813.1 million
Dec. 31, 2025 7.9 billion 783.8 million
Sept. 30, 2025 7.4 billion 760.9 million
June 30, 2025 7.9 billion 734.4 million

UTHR Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 362.5 million 33.9 million
Dec. 31, 2025 173.3 million 39.0 million
Sept. 30, 2025 351.6 million 39.1 million
June 30, 2025 129.5 million 37.8 million

UTHR Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 274.9 million
Dec. 31, 2025 364.3 million
Sept. 30, 2025 338.7 million
June 30, 2025 309.5 million

UTHR Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 2.2 billion - -
Dec. 31, 2025 1.6 billion - -
Sept. 30, 2025 2.8 billion - -
June 30, 2025 3.0 billion - -

UTHR Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 47.2 million
Dec. 31, 2025 47.9 million
Sept. 30, 2025 47.3 million
June 30, 2025 48.3 million

UTHR Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 100.8 million 138.2 million 184.1 million -
Dec. 31, 2025 172.9 million 139.5 million 189.8 million 32.7 million
Sept. 30, 2025 210.5 million 127.5 million 181.8 million 28.3 million
June 30, 2025 62.2 million 134.0 million 190.8 million 31.0 million

UTHR Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 781.5 million 133.4 million
Dec. 31, 2025 790.2 million 103.4 million
Sept. 30, 2025 799.5 million 100.9 million
June 30, 2025 798.6 million 87.6 million

UTHR Revenue by Segment
Graph available only for paid members. Upgrade to see it.

UTHR

Price: $545.96

52 week price:
272.12
609.35

Earnings Per Share: 27.05 USD

P/E Ratio: 21.51

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 115651

Ebitda: 331.7 million

Market Capitalization: 23.2 billion

Links: